Moneygram CEO Talks...
Health Care: Drugs
Pluristem Therapeutic (PSTI: NASDAQ)
$3.15 0.09 | 2.94%
05/22/13 - 04:00 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 716.00K | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | -207.00K | -170.00K |
| Gross Operating Profit | 716.00K | 0.00 | 207.00K | 170.00K |
| Selling, General, and Administrative Expenses | 6.57M | 4.48M | 3.14M | 3.42M |
| Research & Development | 9.18M | 6.63M | 4.30M | 3.14M |
| Operating Income before D & A (EBITDA) | -15.03M | -11.11M | -7.23M | -6.39M |
| Depreciation & Amortization | 435.00K | 312.00K | 207.00K | 170.00K |
| Interest Income | 575.00K | 236.00K | 2.00K | 14.00K |
| Other Income - Net | -326.00K | 43.00K | 15.00K | -84.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -15.22M | -11.15M | -7.42M | -6.63M |
| Interest Expense | 12.00K | 13.00K | 31.00K | 8.00K |
| Pre-Tax Income | -15.23M | -11.16M | -7.45M | -6.64M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -14.79M | -10.85M | -7.45M | -6.64M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -14.79M | -10.85M | -7.45M | -6.64M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -14.79M | -10.85M | -7.45M | -6.64M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-14.79M | -10.85M | -7.45M | -6.64M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -14.79M | -10.85M | -7.45M | -6.64M |
| Basic EPS from Continuing Ops. | -0.34 | -0.35 | -0.44 | -0.63 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.34 | -0.35 | -0.44 | -0.63 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.34 | -0.35 | -0.44 | -0.63 |
| Basic Normalized Net Income/Share | -0.34 | -0.35 | -0.44 | -0.63 |
| EPS fr Continuing Ops. | -0.34 | -0.35 | -0.44 | -0.63 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.34 | -0.35 | -0.44 | -0.63 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.34 | -0.35 | -0.44 | -0.63 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.34 | -0.35 | -0.44 | -0.63 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with PSTI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserJaheer
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User0730
Latest PSTI Headlines from TheStreet
- Pluristem Welcomes Parliamentary State Secretary Of The German Federal Ministry For Environmental, Nature Conservation And Nuclear Safety And The Chairman Of The Charite Berlin-Brandenburg Center For Regenerative Therapies 05.22.13 | 05:05 am
- Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia 05.13.13 | 03:05 am
- Pluristem Develops PLX-RAD Cells For Use In Hematology 05.07.13 | 03:05 am
- Pluristem To Present At Needham Healthcare And Oppenheimer Israeli Investment Conferences In May 2013 04.30.13 | 03:04 am
- Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety In Human Lung Models Of Pulmonary Hypertension 04.29.13 | 03:04 am
- Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine 04.18.13 | 03:04 am
- United Therapeutics Receives Regulatory Approval To Commence Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 04.11.13 | 03:04 am
- Pluristem Announces Scientific And Investment Conferences For April 2013 04.10.13 | 02:04 am
- Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury 03.20.13 | 03:03 am
- United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 02.26.13 | 09:02 am
Press Releases for PSTI
- The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI - Business Wire 12.20.12 | 07:12 pm
- Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock - Business Wire 10.12.10 | 08:10 am
- Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia - Business Wire 09.14.10 | 08:09 am
- Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients - Business Wire 08.30.10 | 08:08 am
- Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain - Business Wire 08.09.10 | 08:08 am
- Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board - Business Wire 08.04.10 | 08:08 am
- Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication - Business Wire 06.28.10 | 08:06 am
- Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences - Business Wire 05.20.10 | 08:05 am
Partner Headlines for PSTI
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Orphan Status Sought for PSTI Drug - Analyst Blog - Zacks 08.31.12 | 06:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - Zacks 08.24.12 | 06:08 pm
- Staring Down The Market With Futuristic Picks - Seeking Alpha 08.23.12 | 08:08 am
